In a filing, ANI Pharmaceuticals Inc revealed its SVP, CHIEF HR OFFICER Davis Krista unloaded Company’s shares for reported $0.13 million on Dec 18 ’25. In the deal valued at $82.40 per share,1,622 shares were sold. As a result of this transaction, Davis Krista now holds 58,564 shares worth roughly $4.94 million.
Then, Cook Meredith sold 400 shares, generating $32,928 in total proceeds. Upon selling the shares at $82.32, the SR. VP, GENERAL COUNSEL & SEC. now owns 74,874 shares.
Before that, TANNENBAUM RENEE P sold 1,800 shares. ANI Pharmaceuticals Inc shares valued at $146,070 were divested by the Director at a price of $81.15 per share. As a result of the transaction, TANNENBAUM RENEE P now holds 25,157 shares, worth roughly $2.12 million.
H.C. Wainwright initiated its ANI Pharmaceuticals Inc [ANIP] rating to a Buy in a research note published on July 10, 2025; the price target was $84. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in mid March with a ‘”a Buy”‘ rating. JP Morgan began covering ANIP with “an Overweight” recommendation on March 12, 2025. Leerink Partners started covering the stock on December 11, 2024. It rated ANIP as “an Outperform”.
Price Performance Review of ANIP
On Monday, ANI Pharmaceuticals Inc [NASDAQ:ANIP] saw its stock jump 10.58% to $84.35. Over the last five days, the stock has gained 7.23%. ANI Pharmaceuticals Inc shares have risen nearly 55.74% since the year began. Nevertheless, the stocks have risen 6.85% over the past one year.
How much short interest is there in ANI Pharmaceuticals Inc?
A steep rise in short interest was recorded in ANI Pharmaceuticals Inc stocks on 2025-12-31, growing by 0.12 million shares to a total of 2.96 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 2.85 million shares. There was a rise of 3.93%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 11, 2024 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $68 price target.
